253Alternate day ganciclovir/foscarnet (Gan/Fos) for cytomegalovirus prophylaxis in at risk allogeneic stem cell transplant related and unrelated recipients is 100% effective in preventing CMV infections  by Shereck, E.B. et al.
Poster  P resentat ions  - Sess ion  II 
250 
PROGRAM OVERVIEW: DISEASES TREATED, TYPES OF TRANS- 
PLANTS, REGIMENS AND OUTCOMES IN AN OUTPATIENT BLOOD 
AND MARROW TRANSPLANT PROGRAM 
WilsoT~, 3/I.C.1; Ki~g, j.i; Scott, L.3/IJ; Pien'e, 7~1x£1; Shamlou, R.1; 
Sa1"aci*~o, G.e; HG3ite, M.t; Agura, E.D.l; Bev'vymmz, R.B.~; Fay, 
J. FFJ; Pkzeivo, L.l; ~'Smce, E.A. I 1. Baylor-$'am'molTs Cgmcev Center 
and Texas Oncology, P.A., Dallas, TX; 2. Baylov UTdvevsity ~>iedical 
Cezltel', Drdlas, TX. 
The Blood and Marrow Transplant program at US Oncology at 
Baylor University Medical Center in Dallas, TX expanded its out- 
patient facility in May 2002 to a 14, 000 square foot facility with 
16 infnsion chairs, 6 private rooms and 15 exam rooms. The out- 
patient clinic is open 7 days a week, from 8 AM until 7PM. There 
are 5 attending physicians, 10 infusion nurses, 5 transplant coordi- 
nators, 1 pharmacist, pharmacy technicians and numerous admin- 
istrative support personnel. The outpatient clinic has its own 
pharmacy infusion satellite and offers laboratory selwices. In 2001, 
we performed 168 total transplants with 26 (15%) of those being 
initiated on an outpatient basis. In 2002, year to date, we have per- 
formed a total of 109 transplants, with 25 (23 %) of patients being 
done primarily on an outpatient basis. Of the 25 patients treated 
in 2002, the diseases include AML (2), MDS (1), CML (1), 
Hodgkin's Disease (2), Multiple Myeloma (4), NHL (1~), Ovarian 
(1) and Waldenstrom's Macroglobulinemia (1). There were 17 
autologous transplants, 3 allogeneic sibling transplants, and 5 
lnatched-unrelated donor transplants done on an outpatient basis. 
The preparative regimens used in the outpatient transplants 
include BEAM (8), Melphalan (5), ThioTepa/TBI (2), BUS/CTX 
(2), Carbo/TT (1), and CTX/TBI (1). Six patients received non- 
ablative transplants using Flud/TBI (5) and Flud/CTX (1). Of the 
25 outpatients reated, 12 (48%) had to be admitted within the 
first 30 days of transplant for a median of 3 days. The primary rea 
sons for admission include mucositis, nausea/vomiting and febrile 
neutropenia. There were 23 of 25 patients (92%) alive at Day 90 
post transplant. Of the patients treated in 2002, there have been 2 
deaths, 1 due to complications of recurrent AML, and 1 due to 
graft-versus-host-disease. When appropriate resources are avail- 
able, outpatient transplants can be safe and effective in selected 
patients. 
ALT before transplant may be highly predictive of early toxic 
death after IISCT. At our institution, Bu/Cy regimen was used 
frequently and may be related to these results. 
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VALACYCLOVIR COMPARED TO ACYCLOVIR FOR 
CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC STEM CELL 
TRANSPLANTS RECIPIENTS 
Artz, A.S4 Dieter/e, N.; Gekns, J.; Pm-snd, S'., l,arsol~, R.; Stock, k~; 
Da/ighevty, C.; Zimme'lwla*z, T.; Odemke, 0.; Smith, S.; ITmz Besie*l, 
K. Hematolog/Om'ology, UJfiversity of Chicago, Chicago, [L.
Conditioning regimens using alemmzumab (Campath -1H) are 
associated with rates of cytomegalovirus (CMV) infection as high 
as 85-100% in seropositive donor/recipient pairs. High dose acy 
clovir reduces the incidence of CMV viremia. A recent random- 
ized study demonstrated a further eduction in CMV viremia with 
the use of high dose oral valacyclovir after myeloablative trans- 
plantation(Ljungman Blood 2002). We analyzed CMV positive 
donor and/or recipient subjects who underwent an allogeneic 
SCT protocol conditioned with fludarabine 30 mg/m2/d (D-7 to 
D-3), alemtuzumab 20 mg/d (D-7 to D-3), and melphalan 140 
rag/m2 (D-2). All patients initially received acyclovir prophyla:ds. 
CMV infection was defined as any positive CMV test by poly- 
merase chain reaction (PCR), antigen test, or culture. Early (dur- 
ing hospitalization) CMV infection was identified in 6/26 subjects 
at a median of 20 days despite acyclovir prophylaxis. Upon dis- 
charge, the initial nine patients received oral acyclovir (usually 
800mg po qid). After a policy change, the subsequent 11 patients 
received valacyclovir (2 gr po qid). Of the patients who did not 
reactivate in the hospital, 6/9 on oral acyclovir and 3/11 on vala- 
cylovir developed infection, respectively (p= 0.07). One patient 
with CMV viremia and adenovirus in the urine died on day 121 
with an interstitial puhnonary infiltrate. At autopsy, occasional 
alveolar cells were positive for CMV. In smnlnary, oral valacy- 
clovir tended to be more effective than acyclovir at reducing reac- 
tivation after hospital discharge. These data further confirm the 
high incidence of CMV reactivation with alemtuzmnab based con- 
ditioning regimens despite aggressive prophylaxis. Alternative reg- 
imens to reduce early CMV reactivation are needed. 
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PROGNOSTIC FACTORS FOR DAY 100 TRANSPLANT RELATED MOR- 
TALITY (DAY I00 TRM) FOLLOWING HEMATOPOIETIC STEM CELL 
TRANSPLANTATION (HSCT): A RETROSPECTIVE ANALYSIS OF 459 
PATIENTS TRANSPLANTED AT A SINGLE INSTITUTION 
3/lori, S.; TmTaka, ):; Ohashi, K.; Akiyama, H.; I01ku, LI.; Hirmna, 
K.; Sasnki, T.; Sakamaki, H. Tokyo Metropolitan Komagome Hospital, 
Bmzkyo-ku, Tokyo, ffapa*~. 
Objective: To determine predictive factors for non-relapse 
mortality before day100 (day 100-TRM) following HSCT. 
Patients: Consecutive 459 patients (pts) who received HSCT at 
Tokyo Metropolitan Komagome Hospital between January. 1990 
and December 200I. Median age was 43 yrs (range, 0-67) and 277 
were male. Among them, 354 were allograft recipients (211 from 
related, 139 from unrelated and 4 from syngeneic donor) and 
remaining 105 received autologous HSCT. The preparative r gi- 
mens were 12Gy of TBI based (130pts), busulfan based (227pts) 
or others (102pts). Results: Day-100 TRM occurred in 40 pts and 
Kaplan Meier estimate of the incidence was 9.0%. In univariate 
analysis, day-100 TRM occurred more frequently among pts with 
allograft han autograft (10.7% vs 3.1%, Logrank P = 0.024). 
Among pretransplant variables, serum ALT greater than 50 IU/L 
(21.8% vs 6.1%, P < 0.0001) was the most significant factor p e- 
dicting day-100 TRM though Age older than 44 (12.1% vs 8.0%, 
P = 0.16), TBI containing regimen (9.5% vs 8.9%, P = 0.81), vital 
capacity less than predicted (12.9% vs 9.6%, P = 0.34), FEV1.0 
less than 80% of total expiratory volume (9.7% vs 8.9%, P - 0.93) 
or ejection fraction less than 60% (12.4% vs I1.6%, P = 0.80) 
were not significantly associated with day 100 TRM. In Cox 
regression model, allograft and serum ALT were independent 
predictors adjusted for other factors. Conclus ion:  High serum 
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ALTERNATE DAY GANCICLOVIR/FOSCARNET (GAN/FOS) FOR 
CYTOMEGALOVIRUS PROPHYLAXIS IN AT RISK ALLOGENEIC STEM 
CELL TRANSPLANT RELATED AND UNRELATED RECIPIENTS IS 100% 
EFFECTIVE IN PREVENTING CMV INFECTIONS 
S',~et'eck, E.B.; Be~mevtlO,, 0.; Coo~zey, ]s'.3/l.; Herrisom L.; vml de 
UeJ~, C.; f~ischhover, C.; FUolowlzik, K.; Del Toro, G.; B~wlley, ~'i.; 
Geov~'e, D.; Galwi11, ft.; Cairo, M.S. ChildreJ~5" Hospital of Ne~, York 
PT"eskyterim~, Cohmzbia UTziversity, New }~7"te, NY. 
The incidence of cytomegalovirus (CMV) infection post 
AlloSCT has been reduced by prophylactic Gan (56% to 20%) 
(Winston DJ et al, Ann Intern Med 1993; 118:179), but has been 
associated with significant hematopoietic toxicity and secondary 
graft failures. An alternative ffective agent against CMV is Fos 
(Oberg Bet  al, Pharmacol Ther 1989; 40:1213), but is associated 
with nephrotoxicity and electrolyte imbalances. Since both Gan 
and Fos are effective against CMV but have different oxicity pro- 
files, we evaluated the efficacy and safety of alternate day Gan/Fos 
for CMV prophylaxis. MloSCT pts (n-9) that were serologically 
CMV (-) donor/(-) recipient received leukodepleted blood prod- 
ucts (LDBP). 16 pts who were CMV (+) and/or had a CMV (+) 
donor received prophylaxis with IV Fos at 90 mg/kg Q48II alter- 
nating with [V Gan at 5 mg/kg Q48H, initiated at ANC 
_>7507mm 3 until Day +100. M:F 9:7; age 9.5 -+ 6.6 (0.8-18 yr); 1 
APL CR2, 1 Wihns' SD, 1 Hurler's SD, 2 CML CP, 1 AML 
CR2, 1 SAA, 2 ALL CR2, 2 Beta-Thai, 1 ALL CR3, 1 HD PR2, 1 
HD OR2, I ALCL PR, 1 NBL PD; Donors: 5 RPBSC 6/6, 1 
RPBSC 5/6, 3 RBM 6/6, 2 UCB 5/6, 5 UCB 4/6. GVHD prophy- 
laxis: Tacro/MMF. TNC and CD34 for BM/PBSC was 6.6 _+ 6.I 
xl0S/kg and 5.2 -+ 3.1 x 106/kg, and UCB + SD were 4.9 _+ 5.4 
xl07/kg and 2.4 + 1.6 x 10S/kg, respectively. Despite an incidence 
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of 48% grade II-IV AGVHD (N=12), none (16 Fos/Gan and 9 
LDBP) developed systemic CMV infection. No pts developed pri 
real T or secondary graft failure or grade III/IV hematological toxi- 
city 2 ° to Gan. SeveraI pts. developed transient nephrotoxicity and 
electrolyte imbalances, however all patients were on at least two 
other nephrotoxins: lipo amphotericin B (n=16), tacro/cyclo 
(u=14/2), anainoglycosides (n=4), vancomycin (n=10). No pt. 
developed permanent renal dysfunction, however dose reductions 
of Fos/Gan occurred in 7~% of pts. The probability of l-yr OS 
was 72%. In conclusion, CMV prophyla~s in AlloSCT recipients 
with LDPB in (-)R (-)D and Gan/Fos appears to be tolerable and 
100% effective in preventing CMV disease. This approach 
appears to reduce hematological toxicity of previously reported 
daiIy prophylactic Gan, but may be associated with Fos-induced 
transient nephrotoxicity, especially in combination with other 
nephrotoxic agents. 
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DIGENE HYBRID CAPTURE (DHC) CMV DNA ASSAY COMPARED TO 
CMV CULTURE AND INCIDENCE OF CMV DISEASE IN ALLOGENEIC 
HEMATOPOIETIC STEM CELL TRANSPLANTION (ASCT) 
Trevi'no, A?; Shaagh~ze~s),, P J; Hztdak, p.44 Lmzzk/'oi~, S.;; Bacbie'r, 
C ~; Le3/Iaistve, C.FJ 1. Texas 7qra,zsphz~t I zstit~te, Sar~ A~toMo, TX," 
2. ghffve'rsity of Texas Health Scie~ee Ce~ter at &m A~to~io, Sm~ 
Auto,do, Tk," 3. Joh,s Hopki~zs U~zive~'sit~, Balti~o~'e, MD; 4. &e~th- 
west Texas Methodist Hoapital, Sm~ A~ztonio, TX. 
CMV disease in CMV sero-positive patients post ASCT ranges 
from 21-43% and can be a significant cause of morbidity and mor- 
tality in this patient popuIation. The DHC CMV DNA assay uses 
CMV RNA probes which hybridize with the patient CMV DNA 
and when these hybrids are exposed to alkaline phosphatase they 
can be detected by chemiluminescence. The DHC assay is easy to 
perform and results are rapidly available in 24 to 48 hours. We 
retrospectively reviewed 104 ASCT patients transplanted between 
January 1998 and September 2002. Patients were screened weekly 
for the detection of CMV in blood, urine, and throat by culture 
and shell spin. The DHC CMV assay was also done weekly on 
blood samples fi'om all patients and a value of 2.1 pcg/ml was con- 
sidered positive. CMV disease was defined as evidence of tissue 
invasive disease. Thirteen of the 104 patients had positive CMV 
culture or shell spin results while 46 patients had positive DHC 
assay results. Twelve of the 13 patients with positive culture or 
shell spin results also had positive DHC assay results. One patient 
had a negative DHC assay but a positive urine shell spin. Only 
one patient had docmnented CMV disease with viral inclusions 
consistent with CMV found in the lung on autopsy. This patient 
had negative cultures, shell spin, and DHC CMV assay results and 
was on empiric gancyclovir prior to their death. The sensitivity 
and specificity of the DHC assay compared to CMV culture or 
shell spin was 92% and 63% respectively. In conclusion, the DHC 
assay is a sensitive test for detecting CMV and alIows }br the rapid 
institution of pre-emptive therapy that has resulted in a low insti- 
tutionai incidence of CMV disease. 
pos~t,,ie DF ~pOsitive cultulti,!~ s l!l,vphll negative cu]ti! or shell spin 
chemotherapy. Current data, however, does not specifically 
address whether the use ofrHu Epo in autologous stem cell trans- 
plant patients ignificantly reduces the number of RBC transfu- 
sions, leading to improved quality of life. Retrospectively, we eval- 
uated RBC transfusion usage in similar patient cohorts before and 
after the introduction of rHu-Epo in a single institutional setting. 
Data were reviewed from 111 nol~- rHu-Epo treated and 58 rHu- 
Epo treated adult non-leukemic autologous tem cell transplant 
patients drawn from a 5-year period. Beginning March 2002, a 
uniform institutional protocol for rHu-Epo usage was established 
(40, 000 units sq qweek through day +40 or upon achieving asus- 
tained HCT level of 35%). All patients received similar dosages of 
GNI-CSF post transplant (300mcg/day +4 through ANC recovery 
of 1.5). All patients had similar disease types, identical mobiliza- 
tion protocols (using G-CSF alone), similar infused CD34+ 
counts and followed identical protocol guidelines for RBC trans 
fusions. The rHu-Epo treated cohort resulted in an average of 3.2 
units of RBCs transfused through day +28 as compared to 3.8 
units in the non- rHu-Epo treated group (p=.07). In conclusion, 
tim data suggests that the use of rHu-Epo in autologous stem cell 
transplant patients may reduce the need for RBC transfusions by 
15%. Future studies using various sequencing or dosing of ery- 
thropoetin may provide a greater eduction in RBC usage in 
autologous stem cell transplant patients. 
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UTILIZING A CUSTOMIZED EPIDEMIOLOGICAL, DRUG-SUSCEPTIBILI- 
TY DATABASE TO MONITOR RESISTANCE PATTERNS AND TRENDS 
TO MAKE APPROPRIATE EMPIRIC ANTIBIOTIC SELECTIONS FOR 
BLOOD AND MARROW TRANSPLANT RECIPIENTS 
I, Uhite, 3/i.J; MnmlomTe, K.:; Saracino, G.~-; ShaJ~z/ol~, R.1; Agm'a, 
E. D. l; BeIv'ylllall, R. I; Ph~ei,v, L. 1; Fay, 7 W. l; 3/lmzth L. e; k~*we, E. l 
l. Baylov-SmmHolzs Gt~zcer CeJztel, Texas O*~eology, P.A,, Dallas, TX; 
2. B~O&r UniveTsi{y 3/ledkrd CenteJ, Dallas, T)L 
We followed all blood and marrow transplant patients over a 2 
year period, monitoring epidemiological trends and drug suscepti- 
bility information to choose the most appropriate mpiric antibi- 
otic selection for our febrile, neutropenic patients. The most com- 
monly seen bacterial bloodstream organisms isolated during this 
time period were coagulase n gative staphylococcus (n=323), 
Enterococcus species (n=54) and Pseudomonas species (n=42). 
Each time a gram-negative organism was isolated, it was tested 
against he institutions standardized drug susceptibility panels. Of 
all the gram negative isolates tested, Piperacillin/Tazobactam 
(pip/tazo) performed the best in our patient population, being 
reported as susceptible 107 times it was tested, resistant 41 times, 
and intermediate 5 times. The next 2 antibiotics with the highest 
susceptibilities were ceftazidilne and cefepime. When monitoring 
Pseudomonas resistance patterns over the 2 year period, the least 
resistance was seen with pip/tazo and cefepime, with an average 
resistance of approximately 30 percent. The lowest sensitivities 
were observed with imipenem and the quinolones. Based on the 
data gathered in this database, the use of pip/tazo appears to be 
the most appropriate beta-lactam selection for our patient popula- 
tion for empiric management of febrile neutropenia. In addition 
to providing coverage against most strains of Pseudomonas seen in 
our population, it also offers the advantage of providing some 
enterococcal coverage, which was also observed to be one of our 
most predominant organisms. Such a database allows for a 
prospective means of developing rotational antibiotic selections. 
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EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOETIN ON 
RED CELL TRANSFUSIONS IN NON-LEUKEMIC ADULT AUTOLOGOUS 
STEM CELL TRANSPLANTS: A RETROSPECTIVE EVALUATION 
Paivmm~:, ~ l; Bez,eridge, 3/1.~; Bagshaw, K J; SIJel"idml, 3/1.:; O'rlojf 
G. l I. Failfa.v Ste'm Cell Tra~lspl~rl~t Program INOI,~4 I"aiJfzx Hospital 
Ca'mer CeJete'J; Faaflx, I'~t; 2. INOb~t Fai*fll:c Hospital, PaiJfmv, ~'~4. 
Recombinant Human Erythropoetin (rHu-Epo) reduces the 
number of Red Blood Cell (RBC)transfusions and improves per- 
formance status in patients receiving myelosuppressive 
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SUDDEN BILATERAL VISUAL LOSS DUE TO DISSEMINATED FUSARIO- 
SIS DIAGNOSED BY CULTURE AND POLYMERASE CHAIN REACTION 
l'~lsUtes, J.A.; BelT-Josep,~, A.M.; ShTgb, S.; Chal~dl"asekar, P.H.; 
Abracns, G.H,(; P/am; 0.; RezaeL K Detroit ~ledi~vd CeT~tev-I,~zyTle 
State Uldz~e/sit 3, School of 34ediei1~e, Detroit,, 3/11. 
Invasive fungal infections (IFI) have become a major cause of 
morbidity and mortality in the bone marrow transplant popula- 
tion. One of the greatest challenges in these patients i  to make an 
early diagnosis of an [FI. We describe a patient with ANIL who 
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